Pancreatic cancer screening

Chris M. Lindquist*, Frank H Miller, Nancy Ayers Hammond, Paul Nikolaidis

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: This article reviews the current evidence surrounding pancreatic cancer screening. The current targets of screening include identification of early pancreatic cancer, as well as the two most important precursor lesions; intraductal papillary mucinous neoplasm and high grade pancreatic intraepithelial neoplasia. Given the relatively low incidence of pancreatic adenocarcinoma in the general population, patients with elevated risk based on family history or an underlying genetic syndrome are felt to be the most appropriate patients to undergo screening. Methods: An extensive review of the literature was performed and the major findings of the available literature regarding pancreatic screening are reviewed in detail. Results: Several prospective trials have evaluated pancreatic cancer screening in high-risk groups. The results of those trials are summarized in this article. Current consensus guidelines and recommendations from the International Cancer of the Pancreas Screening Consortium Summit are also discussed. Conclusions: The exact benefit of pancreatic cancer screening remains unclear at this time, but emerging evidence suggests that there is a window of opportunity to detect precursor lesions and early pancreatic adenocarcinomas in high-risk patient populations. Better understanding of the pathway of carcinogenesis will hopefully improve our ability to detect early, resectable pancreatic carcinomas, and provide a mortality benefit to patients at significantly elevated risk of pancreatic adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)264-272
Number of pages9
JournalAbdominal Radiology
Volume43
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Pancreatic Neoplasms
Early Detection of Cancer
Adenocarcinoma
Aptitude
Population
Neoplasms
Consensus
Carcinogenesis
Guidelines
Mortality
Incidence

Keywords

  • EUS
  • Familial pancreatic cancer
  • MRI
  • Pancreatic adenocarcinoma screening
  • Pancreatic cancer screening
  • Pancreatic cancer screening guidelines

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology
  • Urology

Cite this

@article{ee396670f3fb449f8af4ff7756ec9c99,
title = "Pancreatic cancer screening",
abstract = "Purpose: This article reviews the current evidence surrounding pancreatic cancer screening. The current targets of screening include identification of early pancreatic cancer, as well as the two most important precursor lesions; intraductal papillary mucinous neoplasm and high grade pancreatic intraepithelial neoplasia. Given the relatively low incidence of pancreatic adenocarcinoma in the general population, patients with elevated risk based on family history or an underlying genetic syndrome are felt to be the most appropriate patients to undergo screening. Methods: An extensive review of the literature was performed and the major findings of the available literature regarding pancreatic screening are reviewed in detail. Results: Several prospective trials have evaluated pancreatic cancer screening in high-risk groups. The results of those trials are summarized in this article. Current consensus guidelines and recommendations from the International Cancer of the Pancreas Screening Consortium Summit are also discussed. Conclusions: The exact benefit of pancreatic cancer screening remains unclear at this time, but emerging evidence suggests that there is a window of opportunity to detect precursor lesions and early pancreatic adenocarcinomas in high-risk patient populations. Better understanding of the pathway of carcinogenesis will hopefully improve our ability to detect early, resectable pancreatic carcinomas, and provide a mortality benefit to patients at significantly elevated risk of pancreatic adenocarcinoma.",
keywords = "EUS, Familial pancreatic cancer, MRI, Pancreatic adenocarcinoma screening, Pancreatic cancer screening, Pancreatic cancer screening guidelines",
author = "Lindquist, {Chris M.} and Miller, {Frank H} and Hammond, {Nancy Ayers} and Paul Nikolaidis",
year = "2018",
month = "2",
day = "1",
doi = "10.1007/s00261-017-1308-z",
language = "English (US)",
volume = "43",
pages = "264--272",
journal = "Abdominal Radiology",
issn = "2366-004X",
publisher = "Springer New York",
number = "2",

}

Pancreatic cancer screening. / Lindquist, Chris M.; Miller, Frank H; Hammond, Nancy Ayers; Nikolaidis, Paul.

In: Abdominal Radiology, Vol. 43, No. 2, 01.02.2018, p. 264-272.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pancreatic cancer screening

AU - Lindquist, Chris M.

AU - Miller, Frank H

AU - Hammond, Nancy Ayers

AU - Nikolaidis, Paul

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Purpose: This article reviews the current evidence surrounding pancreatic cancer screening. The current targets of screening include identification of early pancreatic cancer, as well as the two most important precursor lesions; intraductal papillary mucinous neoplasm and high grade pancreatic intraepithelial neoplasia. Given the relatively low incidence of pancreatic adenocarcinoma in the general population, patients with elevated risk based on family history or an underlying genetic syndrome are felt to be the most appropriate patients to undergo screening. Methods: An extensive review of the literature was performed and the major findings of the available literature regarding pancreatic screening are reviewed in detail. Results: Several prospective trials have evaluated pancreatic cancer screening in high-risk groups. The results of those trials are summarized in this article. Current consensus guidelines and recommendations from the International Cancer of the Pancreas Screening Consortium Summit are also discussed. Conclusions: The exact benefit of pancreatic cancer screening remains unclear at this time, but emerging evidence suggests that there is a window of opportunity to detect precursor lesions and early pancreatic adenocarcinomas in high-risk patient populations. Better understanding of the pathway of carcinogenesis will hopefully improve our ability to detect early, resectable pancreatic carcinomas, and provide a mortality benefit to patients at significantly elevated risk of pancreatic adenocarcinoma.

AB - Purpose: This article reviews the current evidence surrounding pancreatic cancer screening. The current targets of screening include identification of early pancreatic cancer, as well as the two most important precursor lesions; intraductal papillary mucinous neoplasm and high grade pancreatic intraepithelial neoplasia. Given the relatively low incidence of pancreatic adenocarcinoma in the general population, patients with elevated risk based on family history or an underlying genetic syndrome are felt to be the most appropriate patients to undergo screening. Methods: An extensive review of the literature was performed and the major findings of the available literature regarding pancreatic screening are reviewed in detail. Results: Several prospective trials have evaluated pancreatic cancer screening in high-risk groups. The results of those trials are summarized in this article. Current consensus guidelines and recommendations from the International Cancer of the Pancreas Screening Consortium Summit are also discussed. Conclusions: The exact benefit of pancreatic cancer screening remains unclear at this time, but emerging evidence suggests that there is a window of opportunity to detect precursor lesions and early pancreatic adenocarcinomas in high-risk patient populations. Better understanding of the pathway of carcinogenesis will hopefully improve our ability to detect early, resectable pancreatic carcinomas, and provide a mortality benefit to patients at significantly elevated risk of pancreatic adenocarcinoma.

KW - EUS

KW - Familial pancreatic cancer

KW - MRI

KW - Pancreatic adenocarcinoma screening

KW - Pancreatic cancer screening

KW - Pancreatic cancer screening guidelines

UR - http://www.scopus.com/inward/record.url?scp=85028346976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028346976&partnerID=8YFLogxK

U2 - 10.1007/s00261-017-1308-z

DO - 10.1007/s00261-017-1308-z

M3 - Article

C2 - 28840303

AN - SCOPUS:85028346976

VL - 43

SP - 264

EP - 272

JO - Abdominal Radiology

JF - Abdominal Radiology

SN - 2366-004X

IS - 2

ER -